Targeting chemokines in proteinuria-induced renal disease

Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis

(2012) John G. Cumming et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The GHS-R Blocker D-[Lys3] GHRP-6 Serves as CCR5 Chemokine Receptor Antagonist

(2012) Kalpesh Patel et al.   International Journal of Medical Sciences

CCR5 Antagonist TD-0680 Uses a Novel Mechanism for Enhanced Potency against HIV-1 Entry, Cell-mediated Infection, and a Resistant Variant

(2012) Yuanxi Kang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

CCL5, CCR1 and CCR5 in murine glioblastoma: Immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5

(2012) Kien Pham et al.   JOURNAL OF NEUROIMMUNOLOGY

TWEAK (tumor necrosis factor–like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation

(2012) María Concepción Izquierdo et al.   KIDNEY INTERNATIONAL

Structural Insights from Binding Poses of CCR2 and CCR5 with Clinically Important Antagonists: A Combined In Silico Study

(2012) Gugan Kothandan et al.   PLoS One

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

(2012) Dona L Fleishaker et al.   ARTHRITIS RESEARCH & THERAPY

Antiproteinuric Effect of Chemokine C-C Motif Ligand 2 Inhibition in Subjects with Acute Proliferative Lupus Nephritis

(2011) Alessandro Ble et al.   AMERICAN JOURNAL OF NEPHROLOGY

Dual Blockade of the Homeostatic Chemokine CXCL12 and the Proinflammatory Chemokine CCL2 Has Additive Protective Effects on Diabetic Kidney Disease

(2011) Murthy N. Darisipudi et al.   AMERICAN JOURNAL OF PATHOLOGY

Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist

(2011) Changsheng Zheng et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A dual CCR2/CCR5 chemokine antagonist, BMS-813160?

(2011) Peter Norman   EXPERT OPINION ON THERAPEUTIC PATENTS

Association of Circulating Fractalkine (CX3CL1) and CX3CR1+CD4+ T Cells with Common Carotid Artery Intima-Media Thickness in Patients with Chronic Kidney Disease

(2011) Ashok Kumar Yadav et al.   Journal of Atherosclerosis and Thrombosis

Correlations of Urinary Biomarkers, TNF-Like Weak Inducer of Apoptosis (TWEAK), Osteoprotegerin (OPG), Monocyte Chemoattractant Protein-1 (MCP-1), and IL-8 with Lupus Nephritis

(2011) Amal El-shehaby et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Discovery, Optimization, and Pharmacological Characterization of Novel Heteroaroylphenylureas Antagonists of C−C Chemokine Ligand 2 Function

(2011) Edgardo Laborde et al.   JOURNAL OF MEDICINAL CHEMISTRY

Renal TLR4 mRNA Expression Correlates with Inflammatory Marker MCP-1 and Profibrotic Molecule TGF-β1 in Patients with Chronic Kidney Disease

(2011) Julia Lepenies et al.   NEPHRON CLINICAL PRACTICE

Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate

(2010) Daniëlle M. Gerlag et al.   ARTHRITIS AND RHEUMATISM

Relationship between Oxidative Stress and Inflammatory Cytokines in Diabetic Nephropathy

(2010) Ahmed A. Elmarakby et al.   Cardiovascular Therapeutics

Anti-inflammatory effects of the GABAB receptor agonist baclofen in allergic contact dermatitis

(2010) Beatrice Duthey et al.   EXPERIMENTAL DERMATOLOGY

Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential

(2010) Jan G D'Haese et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

NF- B in Renal Inflammation

(2010) A. B. Sanz et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice

(2010) Young Sun Kang et al.   KIDNEY INTERNATIONAL

Urinary monocyte chemoattractant protein-1 excretion in children with glomerular proteinuria

(2010) Anna Wasilewska et al.   SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY

Discovery of a Potent and Orally Bioavailable CCR2 and CCR5 Dual Antagonist

(2010) Alexander Pasternak et al.   ACS Medicinal Chemistry Letters

Efficient Renal Recruitment of Macrophages and T Cells in Mice Lacking the Duffy Antigen/Receptor for Chemokines

(2009) Volker Vielhauer et al.   AMERICAN JOURNAL OF PATHOLOGY

Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes

(2009) S. G. Sayyed et al.   DIABETOLOGIA

SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects

(2009) O. Holz et al.   EUROPEAN RESPIRATORY JOURNAL

Chemokine receptor antagonists: part 2

(2009) James E Pease et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

An engineered CX3CR1 antagonist endowed with anti-inflammatory activity

(2009) Karim Dorgham et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Rosiglitazone activation of PPARγ suppresses fractalkine signaling

(2009) Yihong Wan et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Nicotinamide Glycolates Antagonize CXCR2 Activity through an Intracellular Mechanism

(2009) D. Y. Maeda et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Nonpeptidergic Allosteric Antagonists Differentially Bind to the CXCR2 Chemokine Receptor

(2009) P. de Kruijf et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A novel CXCL8 protein-based antagonist in acute experimental renal allograft damage

(2009) Jens Bedke et al.   MOLECULAR IMMUNOLOGY

Anti-Ccl2 Spiegelmer Permits 75% Dose Reduction of Cyclophosphamide to Control Diffuse Proliferative Lupus Nephritis and Pneumonitis in MRL-Fas(lpr) Mice

(2008) O. Kulkarni et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease

(2008) Kevin S. Eardley et al.   KIDNEY INTERNATIONAL